ARO-DIMERPA

PreclinicalSmall molecule

Arrowhead Pharmaceuticals

ARO-DIMERPA is one of 37 small molecule programs targeting Hyperlipidemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperlipidemiaActive, not recruiting

Hyperlipidemia; MixedRecruiting

HyperlipidemiaPhase 1/Phase 2

Active, not recruiting

Hyperlipidemia; MixedPreclinical

Recruiting

Competition

Competitive Landscape

97 competitors in Hyperlipidemia

#DrugCompanyPhaseTrials

Repatha

Amgen

Phase 3

3 2

Avapro

Sanofi

Phase 3

2 3

Lorelco

Sanofi

Phase 3

1 4

Praluent

Regeneron

Phase 3

1 5

Micardis

Boehringer Ingelheim

Phase 3

3 6

Lesinurad

EEsperion Therapeutics, Inc.

Phase 3

2 7

Reyataz

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 8

Zocor

OOrganon and Co

Phase 3

1 9

Tricor

JJagotec

Phase 3

1 10

Isentress

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalRecruiting

Hyperlipidemia; Mixed

NCT07223658

Clinical

Trials by Indication[1]

Hyperlipidemia; Mixed1 trial

Phase 1/2a, Double-blind, Placebo-controlled, Single and Multiple Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ARO-DIMERPA in Adult Subjects With Mixed Hyperlipidemia

Recruiting· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Preclinical·NCT07223658·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ARO-DIMERPA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARO-DIMERPA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARO-DIMERPA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arrowhead Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Arrowhead Pharmaceuticals

ARO-DIMERPA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Hyperlipidemia; Mixed1 trial

References

Drug Info

Quick Facts

Related News